Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2021-02-16 Major Shareholding Noti…
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2021-02-16 English
AMENDMENT TO SCHEDULE 13G
Major Shareholding Notification
2021-02-13 English
BIOLINERX LTD.
Major Shareholding Notification
2021-02-12 English
AMENDMENT NO. 1 TO SCHEDULE 13G
Major Shareholding Notification
2021-01-29 English
PRELIMINARY PROSPECTUS SUPPLEMENT dated January 11, 2021
Capital/Financing Update Classification · 98% confidence The document is titled "PRELIMINARY PROSPECTUS SUPPLEMENT (To prospectus dated January 11, 2021)" and details an offering of American Depositary Shares (ADSs), including pricing tables, underwriting details, and a table of contents for both the supplement and the accompanying prospectus. This structure is characteristic of a registration statement filed with the SEC to offer securities to the public. While it is a prospectus supplement, the core activity described is the offering and sale of securities, which falls under the scope of financing activities. The most appropriate category among the provided options for a document detailing a public offering, pricing, and underwriting is Capital/Financing Update (CAP). It is not a standard 10-K, ER, or IR, but a specific offering document.
2021-01-23 English
PRELIMINARY PROSPECTUS SUPPLEMENT dated January 11, 2021
Capital/Financing Update Classification · 95% confidence The document explicitly states it is an 'Immediate Report' filed under Israeli securities regulations, referencing a 'PRELIMINARY PROSPECTUS SUPPLEMENT (To prospectus dated January 11, 2021)'. It also mentions the attachment of a PDF file related to this supplement. A prospectus supplement is a document related to the offering or sale of securities, which falls under financing activities or capital structure changes. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate classification for a preliminary prospectus supplement, as it directly relates to a potential capital raise or financing event. The document is short and announces the filing/attachment of the primary document, but since the content itself is about a prospectus supplement (a core financing document), classifying it as CAP is more specific than the general RPA or RNS fallback, although RPA might also be considered if the focus was purely on the announcement mechanism. However, the subject matter (Prospectus Supplement) strongly points to CAP.
2021-01-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.